NEW YORK CITY, NY / ACCESS Newswire / November 12, 2026 / Alnylam Pharmaceuticals (NASDAQ: ALNY) shareholders lost $58.40 per share on October 29, 2026, when the stock fell 25.13% to close at $174.00 after the Company reported slowing demand for Amvuttra. If you suffered a loss on your Alnylam investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The drop followed the Company's financial results for the third quarter ended September 30, 2026, released that same day. Amvuttra, one of Alnylam's treatments for transthyretin-mediated amyloidosis, accounts for 87.5% of the Company's product sales.

Alnylam reported U.S. total transthyretin demand growth of $81 million for the quarter. For the preceding quarter, that figure was $129 million. Levi & Korsinsky is investigating potential securities law violations at Alnylam.

Investors who purchased Alnylam shares and suffered losses can have their ALNY losses reviewed at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the ALNY Investigation

Q: What is the ALNY securities fraud investigation about?
A: A securities investigation is pending concerning Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) regarding potentially materially false or misleading statements. Shares fell approximately 25.13% after the Company disclosed slowing demand for Amvuttra and U.S. transthyretin demand growth of $81 million, down from $129 million in the prior quarter, causing losses for shareholders.

Q: Who is conducting the ALNY investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased ALNY securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: Who is eligible to participate in the ALNY investigation?
A: Investors who purchased ALNY stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do ALNY investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my ALNY shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ALNY and sold at a loss may still participate in the investigation.

Q: What if my ALNY losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP